Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Sponsor-Investigator phase 2 multicenter, randomized, double-blind, placebo-controlled study to evaluate Leukine in 64 patients with mild to moderate aPAP

Next Previous
Search
Trial Profile

A Sponsor-Investigator phase 2 multicenter, randomized, double-blind, placebo-controlled study to evaluate Leukine in 64 patients with mild to moderate aPAP

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sargramostim (Primary)
  • Indications Pulmonary alveolar proteinosis
  • Focus Therapeutic Use
  • Acronyms PAGE

    • Most Recent Events

    • 09 Apr 2024 New trial record
    • 03 Apr 2024 According to Partner Therapeutics based on data from this study sargramostim received approval from the Japanese Pharmaceuticals and Medical Device Agency (PMDA) to treat Autoimmune Pulmonary Alveolar Proteinosis
    • 03 Apr 2024 Primary endpoint has been met. (improvement in alveolararterial oxygen gradient (A-aDO2) between baseline and week 25)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top